Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.

Lee ShettleEugene B McLaurinJoseph MartelJohn W SeamanGeorges Weissgerber

Published in: Clinical ophthalmology (Auckland, N.Z.) (2022)

Topical ocular licaminlimab demonstrated statistically significant improvement in global ocular discomfort score compared to Vehicle in patients with severe DED, with good tolerability, no increase in IOP, and minimal systemic drug exposure.

Keyphrases

phase ii study
open label
early onset
optic nerve
drug induced
rheumatoid arthritis
locally advanced
placebo controlled
wound healing
clinical trial
emergency department
double blind
optical coherence tomography